Biocompatibles BiodivYsio
This article was originally published in The Gray Sheet
Executive Summary
PMA supplement approval for small vessel over-the wire version of the coronary stent (SV OTW) comes six months after FDA sign-off on the first version of the phosphorylcholine (PC) coated stent - the AS OTW Added Support system. The small vessel version is approved for abrupt or threatened closure on 2.0 mm and 2.5 mm diameter OTW delivery catheters. The AS OTW system is for de novo native lesions with vessel diameters 3.0-4.0 mm. An August 2001 PMA supplement is pending for the OC OTW Optimized Conformability version. Separately, Biocompatibles notes it has submitted an IDE for the 40-center, pivotal U.S. BATMAN II trial of its batimastat MMP inhibitor-coated BiodivYsio stent with PC technology for delivery. The U.S. trial will build upon the Latin American BATMAN pilot and European BRILLIANT trials already underway (1"The Gray Sheet" Nov. 5, 2001, p. 23)...
You may also be interested in...
Biocompatibles BiodivYsio
Phosphorylcholine-coated coronary stent line is complete following PMA supplement approval for the OC OTW optimized conformability over-the-wire version of the device (1"The Gray Sheet" Jan. 7, 2002, In Brief). Already available are the SV OTW version for small vessels and AS OTW added support system. Abbott Laboratories distributes the devices in the U.S...
Biocompatibles Lens Unit Divestiture Could Ripen Firm For Abbott Purchase
Biocompatibles' divestiture of its Eye Care division to Cooper Companies converts the British firm into a pure-play entity in the coronary and drug-coated stent market
Abbott Diagnostics Looking Beyond FDA Consent Decree In 2002
Abbott Labs is forecasting diagnostics sales growth in the "mid to high single-digit" range in 2002, with the final resolution of its consent decree with FDA and a series of planned product launches, including Prism high-throughput automated blood screening system assays